Was generally well tolerated. Side effects are usually mild or moderately expressed and are transient in nature. Below are the adverse events observed in clinical trials or post-market drug.
In evaluating the frequency of occurrence of side effects following the graduation used “very often”including isolated posts. On the part of the system hematopoiesis: rarely – neutropenia, agranulocytosis, thrombocytopenia, increased activity of “liver” transaminases, lymphopenia.immune system: very rare – anaphylactoid reactions (including angioedema), cutaneous and systemic lupus erythematosus. From the nervous system: often – headache pain; sometimes – a violation of taste sensations, including their loss (typically recovery occurs within a few weeks after cessation of treatment). There are some reports of cases of prolonged taste disturbance. In some cases in patients receiving the drug showed a decrease in food intake, which resulted in a significant reduction in weight. Liver: rare – hepatobiliary dysfunction (primarily cholestatic nature), including very rare cases of serious liver failure (some with a fatal outcome or requiring liver transplantation .) On the part of the gastrointestinal tract anavar dosage: very often – a sense of fullness, loss of appetite, indigestion, nausea. Weakly expressed abdominal pain, diarrhea. With the skin side and subcutaneous tissue: very often – not severe skin reactions (rash, urticaria), rarely – severe skin reactions (including Stevens-Johnson syndrome, toxic epidermal necrolysis); psoriasiform rash or exacerbation of psoriasis. Very rarely, there have been cases of hair loss, although a causal link with the administration of the drug has not been established.If by progressive skin rashes, treatment Terbifinom ® should be discontinued. On the part of the musculoskeletal system: very often – arthralgia, myalgia. Other : very rarely – fatigue.
There have been reports of a few cases of overdose (adopted dose amounted to 5 g), in which the observed headache, nausea, epigastric pain and dizziness.
Recommended in case of overdose, treatment involves action on the removal of the drug, primarily by the appointment of activated carbon and gastric lavage; if necessary, symptomatic and supportive therapy.
Interaction with other drugs The influence of other drugs on terbinafine The plasma clearance of terbinafine may be accelerated under the influence of drugs – inducers of metabolism and suppressed under the influence of inhibitors of cytochrome P450. If necessary, the simultaneous application of the above drugs and anavar dosage may require a corresponding correction of the last dosing regimen. Cimetidine may increase the effects of terbinafine or increase its concentration in plasma. Cimetidine reduces the clearance of terbinafine by 33%. Rifampicin may impair the action of terbinafine or reduce its concentration in plasma. Rifampicin increases terbinafine clearance by 100%. The effect of terbinafine on other drugs Studies conducted in vitro and in healthy volunteers show that terbinafine has little capacity to inhibit or enhance the clearance of most drugs that are metabolized by the participation of cytochrome (eg terfenadine, triazolam, tolbutamide or oral contraceptives), except for those that are metabolized with the participation o. Terbinafine does not influence the clearance of antipyrine or digoxin. There are reports of several cases of menstrual disorders in patients treated together with oral contraceptives, although the incidence these disorders are not higher than the average rate of such disorders in patients taking only oral contraceptives. Terbinafine may increase the effects of caffeine or increase its concentration in plasma. Terbinafine caffeine clearance decreases by 20%. In studies in vivo and in vitro have shown that terbinafine inhibits metabolism mediated by the enzymeanavar dosage.
These data may be clinically important for those drugs that are metabolized primarily by the enzyme: tricyclic antidepressants, beta adrenoblokatory. Selective serotonin reuptake inhibitors, antiarrhythmic drugs class 1C and monoamine oxidase inhibitors type B, -. In the case, if the drug is used at the same time has a small range of therapeutic concentrations of Terbinafine decreases the clearance of desipramine by 82%. The ethanol and other hepatotoxic drugs increase the risk of hepatotoxicity. terbinafine may weaken the effect of cyclosporine, and reduce its concentration in plasma.Terbinafine increases the clearance of cyclosporine by 15%.
has been shown that terbinafine inhibits metabolism mediated by the enzyme anavar dosage. It is therefore necessary to carry out continuous monitoring of patients receiving simultaneously with Terbifinom treatment with drugs predominantly metabolized with the participation of the enzyme (such as tricyclic antidepressants, betaadrenoblokatory, selective serotonin reuptake inhibitors, antiarrhythmic drugs class 1C and monoamine oxidase inhibitors type B), if applicable the drug has a small range of therapeutic concentrations at the same time.
Irregular use or premature ending of treatment increases the risk of relapse. If after 2 weeks of treatment, no improvement in the state, it is necessary to re-determine the causative agent and its sensitivity to the drug.
Before and during treatment requires monitoring of liver function.
The treatment must comply with the general rules of hygiene for the prevention of reinfection (via / underwear, footwear ).